secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001193125-24-237196
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio outlines budoprutug development strategy; Phase 1b pMN data shows 60% remission
--------------------------------------------------------------------------------

- Approximately $218M cash at Sept 30, 2024; expected to fund operations through 2027.
- Phase 1b pMN: 3/5 patients achieved complete remission; rapid B-cell depletion and anti-PLA2R reductions.
- Plans to initiate Phase 1b SLE trial and Phase 2 ITP trial in first half 2025, subject to regulatory clearance.
- Subcutaneous formulation advancing; non-clinical data expected first half 2025.
- Full pMN Phase 1b data to be presented at ASN Kidney Week on Oct 24, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312524237196/0001193125-24-237196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312524237196/d889682d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-237196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer